Blog Page 2

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below.

Susan Kling Finston

Nascent life sciences start-ups in the BRICS and other emerging markets face continuing fundraising hurdles, as discussed here and more recently here. So while there have been increasing calls for India’s small-scale entrepreneurs to move from ‘jugaad’ to more Israeli-style start-ups, access to capital has not kept pace with India’s appetite for innovation. Understanding just how limited India’s public funding is for biotech start-ups may help to explain the importance of this issue.

The Indian Department of Biotechnology (DBT) provides the lion’s share of domestic funding for R&D-Intensive Micro-Small & Medium Enterprises (MSMEs). Not taking into account limitations in actual disbursement of budgeted funds, the DBT’s stated funding for the SBIRI, BIPP and other R&D programs amounted to less than $15 million annually in recent years: “For 2013-14, the allocations are merely 90 crores,” (p. 44). Of this total, the lion’s share historically has aided established pharmaceutical / biotech companies.  

Accordingly, the Modi Government should look beyond public sectors funding schemes for biotech startups, where tax incentives to energize Angel Investors may play an important role in dramatically increasing funding for innovative start-ups. Both Israel and the US provide R&D Investment tax credits that serve as effective incentives for funding ‘high risk-high reward’ ventures, with immediate benefits to Angels who traditionally provide seed funding to start-ups at earlier stages than VCs. 

Issues relating to broader tax reforms and the need for tax incentives for high net worth individuals (HNWI) to create a broad class of Angel Investors surfaced over the course of the April 15th CSIS program: Deepening the U.S.-India Commercial Partnership: The First Year of the Modi Government, co-organized by the Wadhwani Foundation and the Ananta Aspen Centre. India’s private sector represents a huge, untapped source of capital to support job creation through funding of R&D-intensive MSMEs.  With a total of 14,800 multimillionaires and 2,700 multimillionaires in Mumbai alone, India ranks in 8th place globally in terms of the number of multimillionaires and is home to the 4th largest number of billionaires around the world.

India ranks in 8th place globally in terms of the number of multimillionaires and is home to the 4th largest number of billionaires around the world

With the right tax incentives, these High Net Worth Individuals (HNWIs) may take flight as a new Angel Investor class, easily surpassing limited public funds available to India’s R&D intensive MSMEs. Giving Angel Investors their wings could help an unprecedented number of MSME innovators, leading to a virtuous circle of job creation and development of new pharmaceutical and biotechnology products that are ‘made in India.’

More information on investment tax credits and how India may benefit through selective adaptation of Israeli and US policies for R&D intensive MSMEs may be found in the Wadhwani Foundation’s Innovation Blueprint Study, available for download here.

 

About the author:
President of Finston Consulting LLC since 2005, Susan works with innovative biotechnology and other clients ranging from start-up to Fortune-100, providing support for legal, transactional, policy and “doing business” issues. Susan has extensive background and special expertise relating to intellectual property and knowledge-economy issues in advanced developing countries including India and South Asia, Latin America and the Middle East North Africa (MENA) region. She also works with governments, and NGOs on capacity building and related educational programs through BayhDole25. Together with biotechnology pioneer Ananda Chakrabarty, she also is co-founder of Amrita Therapeutics Ltd., an emerging biopharmaceutical company based in India with cancer peptide drugs entering in vivo research. Previous experience includes 11 years in the U.S Foreign Service with overseas tours in London, Tel Aviv, and Manila and at the Department of State in Washington DC. For more information on latest presentations and publications please visit finstonconsulting.com.

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them

Click the patents below for more details, or visit DrugPatentWatch.com for more options.

ALOXI (palonosetron hydrochloride)
Helsinn Hlthcare
Patent number: 5,202,333
Expiration Date: Apr 13, 2015


AKYNZEO (netupitant; palonosetron hydrochloride)
Helsinn Hlthcare
Patent number: 5,202,333
Expiration Date: Apr 13, 2015


GATTEX KIT (teduglutide recombinant)
Nps Pharms Inc
Patent number: 5,789,379
Expiration Date: Apr 14, 2015


JUXTAPID (lomitapide mesylate)
Aegerion
Patent number: 5,739,135
Expiration Date: Apr 14, 2015


MYLOTARG (gemtuzumab ozogamicin)
Wyeth Pharms Inc
Patent number: 5,739,116
Expiration Date: Apr 14, 2015


CLEVIPREX (clevidipine)
Medicines Co
Patent number: 5,739,152
Expiration Date: Apr 14, 2015


EMEND (aprepitant)
Merck
Patent number: 5,719,147
Expiration Date: Apr 17, 2015


For more information try a free trial

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them

Click the patents below for more details, or visit DrugPatentWatch.com for more options.

AKYNZEO (netupitant; palonosetron hydrochloride)
Helsinn Hlthcare
Patent number: 5,202,333
Expiration Date: Apr 13, 2015


ALOXI (palonosetron hydrochloride)
Helsinn Hlthcare
Patent number: 5,202,333
Expiration Date: Apr 13, 2015


CLEVIPREX (clevidipine)
Medicines Co
Patent number: 5,739,152
Expiration Date: Apr 14, 2015


GATTEX KIT (teduglutide recombinant)
Nps Pharms Inc
Patent number: 5,789,379
Expiration Date: Apr 14, 2015


JUXTAPID (lomitapide mesylate)
Aegerion
Patent number: 5,739,135
Expiration Date: Apr 14, 2015


MYLOTARG (gemtuzumab ozogamicin)
Wyeth Pharms Inc
Patent number: 5,739,116
Expiration Date: Apr 14, 2015


EMEND (aprepitant)
Merck
Patent number: 5,719,147
Expiration Date: Apr 17, 2015


For more information try a free trial

Drug Patent Expirations for April 2015

Tradename Applicant Generic Name Patent Number Patent Expiration
FAMVIR Novartis famciclovir 5,866,581*PED Apr 4, 2015
FAMVIR Novartis famciclovir 6,124,304*PED Apr 4, 2015
PROVIGIL Cephalon modafinil RE37516*PED Apr 6, 2015
NUVIGIL Cephalon armodafinil RE37516*PED Apr 6, 2015
ADVAIR HFA Glaxo Grp Ltd fluticasone propionate; salmeterol xinafoate 5,674,472*PED Apr 7, 2015
HYCAMTIN Glaxosmithkline topotecan hydrochloride 5,674,872*PED Apr 7, 2015
FLOVENT HFA Glaxo Grp Ltd fluticasone propionate 5,674,472*PED Apr 7, 2015
AKYNZEO Helsinn Hlthcare netupitant; palonosetron hydrochloride 5,202,333 Apr 13, 2015
ALOXI Helsinn Hlthcare palonosetron hydrochloride 5,202,333 Apr 13, 2015
MYLOTARG Wyeth Pharms Inc gemtuzumab ozogamicin 5,739,116 Apr 14, 2015
GATTEX KIT Nps Pharms Inc teduglutide recombinant 5,789,379 Apr 14, 2015
CLEVIPREX Medicines Co clevidipine 5,739,152 Apr 14, 2015
JUXTAPID Aegerion lomitapide mesylate 5,739,135 Apr 14, 2015
EMEND Merck aprepitant 5,719,147 Apr 17, 2015
ABILIFY MAINTENA KIT Otsuka Pharm Co Ltd aripiprazole 5,006,528 Apr 20, 2015
ABILIFY Otsuka aripiprazole 5,006,528*PED Apr 20, 2015
CAVERJECT Pharmacia And Upjohn alprostadil 5,741,523 Apr 21, 2015
EXUBERA Pfizer insulin recombinant human 5,740,794 Apr 21, 2015
OXYTROL Watson Labs (utah) oxybutynin 5,601,839 Apr 26, 2015
OXYTROL FOR WOMEN Bayer Healthcare Llc oxybutynin 5,601,839 Apr 26, 2015
OXYTROL Watson Labs (utah) oxybutynin 5,834,010 Apr 26, 2015
OXYTROL FOR WOMEN Bayer Healthcare Llc oxybutynin 5,834,010 Apr 26, 2015
MAVIK Abbvie trandolapril 5,744,496 Apr 28, 2015
LAMISIL AT Novartis terbinafine 5,681,849*PED Apr 28, 2015
LAMISIL AT Novartis terbinafine hydrochloride 5,681,849*PED Apr 28, 2015
LAMISIL Novartis terbinafine 5,681,849*PED Apr 28, 2015
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

Drug Patent Expirations for April 2015

Tradename Applicant Generic Name Patent Number Patent Expiration
FAMVIR Novartis famciclovir 6,124,304*PED Apr 4, 2015
FAMVIR Novartis famciclovir 5,866,581*PED Apr 4, 2015
PROVIGIL Cephalon modafinil RE37516*PED Apr 6, 2015
NUVIGIL Cephalon armodafinil RE37516*PED Apr 6, 2015
ADVAIR HFA Glaxo Grp Ltd fluticasone propionate; salmeterol xinafoate 5,674,472*PED Apr 7, 2015
HYCAMTIN Glaxosmithkline topotecan hydrochloride 5,674,872*PED Apr 7, 2015
FLOVENT HFA Glaxo Grp Ltd fluticasone propionate 5,674,472*PED Apr 7, 2015
AKYNZEO Helsinn Hlthcare netupitant; palonosetron hydrochloride 5,202,333 Apr 13, 2015
ALOXI Helsinn Hlthcare palonosetron hydrochloride 5,202,333 Apr 13, 2015
JUXTAPID Aegerion lomitapide mesylate 5,739,135 Apr 14, 2015
MYLOTARG Wyeth Pharms Inc gemtuzumab ozogamicin 5,739,116 Apr 14, 2015
GATTEX KIT Nps Pharms Inc teduglutide recombinant 5,789,379 Apr 14, 2015
CLEVIPREX Medicines Co clevidipine 5,739,152 Apr 14, 2015
EMEND Merck aprepitant 5,719,147 Apr 17, 2015
ABILIFY MAINTENA KIT Otsuka Pharm Co Ltd aripiprazole 5,006,528 Apr 20, 2015
ABILIFY Otsuka aripiprazole 5,006,528*PED Apr 20, 2015
CAVERJECT Pharmacia And Upjohn alprostadil 5,741,523 Apr 21, 2015
EXUBERA Pfizer insulin recombinant human 5,740,794 Apr 21, 2015
OXYTROL Watson Labs (utah) oxybutynin 5,601,839 Apr 26, 2015
OXYTROL FOR WOMEN Bayer Healthcare Llc oxybutynin 5,601,839 Apr 26, 2015
OXYTROL Watson Labs (utah) oxybutynin 5,834,010 Apr 26, 2015
OXYTROL FOR WOMEN Bayer Healthcare Llc oxybutynin 5,834,010 Apr 26, 2015
LAMISIL Novartis terbinafine 5,681,849*PED Apr 28, 2015
MAVIK Abbvie trandolapril 5,744,496 Apr 28, 2015
LAMISIL AT Novartis terbinafine 5,681,849*PED Apr 28, 2015
LAMISIL AT Novartis terbinafine hydrochloride 5,681,849*PED Apr 28, 2015
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government.

Click the patents below for more details, or visit TechTransferWatch.com for more options.

F-box protein targeted plant oil production
John B. Ohlrogge, Sari A. Ruuska, Yonghua Li
Michigan State University
Patent number: 9,006,518
Issue Date: April 14, 2015


Method for isolating nucleic acids
Pei-Shin Jiang, Kun-Chan Wu, Yu-Ting Su, Chia-Yun Lin, Siou-Cing Su, Yuh-Jiuan Lin
Industrial Technology Research Institute (ITRI)
Patent number: 9,006,419
Issue Date: April 14, 2015


PCP2 mini-promoters
University of British Columbia
Patent number: 9,006,413
Issue Date: April 14, 2015


Expression vector for pseudonocardia autotrophica
Yoshikazu Fujii, Tadashi Fujii, Akira Arisawa, Tomohiro Tamura
Japan National Institute of Advanced Industrial Science and Technology
Patent number: 9,006,412
Issue Date: April 14, 2015


Endometriosis cell targeting peptide and uses thereof
Michiko Fukuda, Daisuke Aoki, Noriko Nozawa, Michiko Fukuda, Daisuke Aoki, Noriko Nozawa
Sanford-Burnham Medical Research Institute
Patent number: 9,006,404
Issue Date: April 14, 2015


Repeat protein from collection of repeat proteins comprising repeat modules
Michael Tobias Stumpp, Patrik Forrer, Hans Kaspar Binz, Andreas Pluckthun
University of Zurich
Patent number: 9,006,389
Issue Date: April 14, 2015


Compositions and methods for pest control
Ido Bachelet, Ram Sasisekharan, Mark Bulmer, Rebeca B. Rosengaus, Ido Bachelet, Ram Sasisekharan, Mark Bulmer, Rebeca B. Rosengaus
Northeastern University
Patent number: 9,006,212
Issue Date: April 14, 2015


Antisense oligonucleotides against neutral sphingomyelinase and neutral sphingomyelinase inhibitor GW4869 for degenerative neurological disorders
Kalipada Pahan
Rush University Medical Center
Patent number: 9,006,205
Issue Date: April 14, 2015


Method of reducing inflammatory infiltration in subjects with inflammatory lung disease
Department of Health and Human Services
Patent number: 9,006,203
Issue Date: April 14, 2015


Selective reduction of allelic variants
C. Frank Bennett, Michael Hayden, Susan M. Freier, Sarah Greenlee, Jeffrey Carroll, Simon Warby, Eric E. Swayze
University of British Columbia
Patent number: 9,006,198
Issue Date: April 14, 2015


Compositions and methods for diminishing viral infection and inflammation associated with viral infection
Peter D. Katsikis, Alina C. Boesteanu, Sefik S. Alkan
Drexel University
Patent number: 9,006,194
Issue Date: April 14, 2015


Selective targeting agents for mitochondria
University of Pittsburgh
Patent number: 9,006,186
Issue Date: April 14, 2015


Methods of protecting against apoptosis using lipopeptides
Cleveland Clinic
Patent number: 9,006,183
Issue Date: April 14, 2015


Immobilizing fusion protein for effective and oriented immobilization of antibody on surfaces
Hyung Joon Cha, Chang Sup Kim
Pohang University of Science and Technology
Patent number: 9,005,992
Issue Date: April 14, 2015


Selection method of induced pluripotent stem cells
Shinya Yamanaka, Takayuki Tanaka
Kyoto University
Patent number: 9,005,976
Issue Date: April 14, 2015


Method for selecting clone of induced pluripotent stem cells
Hideyuki Okano, Yohei Okada, Shinya Yamanaka, Kyoko Miura
Kyoto University
Patent number: 9,005,975
Issue Date: April 14, 2015


Induction of pluripotent cells
Tongxiang Lin, Sheng Ding
Scripps Research Institute
Patent number: 9,005,968
Issue Date: April 14, 2015


Myc variants improve induced pluripotent stem cell generation efficiency
Shinya Yamanaka, Masato Nakagawa
Kyoto University
Patent number: 9,005,967
Issue Date: April 14, 2015


Generation of pluripotent cells from fibroblasts
William E. Lowry, Kathrin Plath
University of California
Patent number: 9,005,966
Issue Date: April 14, 2015


Regionalised endoderm cells and uses thereof
Gillian Mary Morrison, Joshua Mark Brickman, Ifigenia Oikonomopoulou
University of Edinburgh
Patent number: 9,005,962
Issue Date: April 14, 2015


Buoyant triacylglycerol-filled green algae and methods therefor
Washington University
Patent number: 9,005,955
Issue Date: April 14, 2015


Methods for isolating bacteria
Jean-Paul Leonetti, Stéphanie Texier
Centre National de la Recherche Scientifique
Patent number: 9,005,954
Issue Date: April 14, 2015


Use of
Wim Soetaert, Sofie De Maeseneire, Karen Saerens, Sophie Roelants, Inge Van Bogaert
Ghent University
Patent number: 9,005,923
Issue Date: April 14, 2015


Sensor chip for screening topoisomerase inhibitor and screening method thereof
Chun-Mao Lin, Hsiang-Ping Tsai, Chwen-Ming Shih, Jau-Lang Hwang, Chi-Ming Lee
Taipei Medical University
Patent number: 9,005,922
Issue Date: April 14, 2015


Hybridoma cell line for producing antibody for type II collagen
Chih-Hsin Hung, Chi-Yen Shen, Shyh-Ming Kuo, I-Fen Chen, Shih-Han Wang
I-Shou University
Patent number: 9,005,912
Issue Date: April 14, 2015


Risk markers for cardiovascular disease
Cleveland Clinic
Patent number: 9,005,904
Issue Date: April 14, 2015


Method of deriving progenitor cell line
Agency for Science, Technology and Research
Patent number: 9,005,897
Issue Date: April 14, 2015


Alloy nanoparticles for metal-enhanced luminescence
Venkat R. Bhethanabotla, Sanchari Chowdhury
University of South Florida
Patent number: 9,005,890
Issue Date: April 14, 2015


Membrane proximal region of HIV gp41 anchored to the lipid layer of a virus-like particle vaccine
Ira Berkower
Department of Health and Human Services
Patent number: 9,005,631
Issue Date: April 14, 2015


Biotherapy for pain
James Oliver Dolly, Jiafu Wang, Jianghui Meng
Dublin City University
Patent number: 9,005,628
Issue Date: April 14, 2015


Detection of nucleic acid lesions and adducts using nanopores
Cynthia J. Burrows, Henry S. White, Ryuji Kawano, Aaron M. Fleming, Na An
University of Utah
Patent number: 9,005,425
Issue Date: April 14, 2015


Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Building biotechnology teams: Personality does matter

Go to paper

ABSTRACT: Our study describes a naturally occurring experiment exploring linkages between interdisciplinary team outcomes and personality dimensions, general mental ability, and communication type and frequency. This research took place within the context of an NSF-sponsored bioscience entrepreneurship program that engaged science, health science, law and business students working in cross-disciplinary project teams in the technology commercialization process...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below.

Susan Kling FinstonBack when I wrote ISO A Scientific Revolution in Cancer Research in April of 2013, I truly did not expect to be able to greet the revolution by year’s end. By December 2013, though, Science magazine anointed cancer immunotherapy as the “breakthrough of the year”, and pharmaceutical R&D for oncology immunotherapy has been surging ever since. This is really good news for cancer patients and their families.

But first, the backstory: Cancer remains the leading cause of death in OECD countries and second leading cause of death in the developing world. Despite the investment of over $100 billion dollars and increased understanding of the genetics of cancer tumors, the vast majority of patients still receive highly toxic chemotherapy – either on its own or combined with radiation and/or surgery. As before, cancers may routinely develop resistance to chemotherapies, and radiation may new cancers, placing additional burdens on patients, families and the healthcare system. So the  availability of funding for cancer immunotherapy represents an important hope for commercialization of safer, more sustainable cancer therapies.

Cancer immunotherapy seeks to stimulate the patient’s immune system to attack malignant tumors, recognizing that the central challenge of the disease is the inability of the body to recognize and confront uncontrolled growth of cancer cells. Bacterial immunotherapy in particular has a long history of nearly 150 years with observation that acute bacterial infections could shrink tumors, often contributing to complete remission of cancer. In the late 19th century, physicians in Germany and the United States observed that cancer patients with coincident bacterial infections experienced tumor regression. German physicians W. Busch and F. Fehleisen separately reported tumor regression in cancer patients with erysipelas infection.

Contemporaneous reports from Dr. William B. Coley, a New York surgeon, noted regression of malignant sarcomas in patients suffering from bacterial infections. Dr. Coley then systematically treated bone and soft tissue cancer with a bacterial vaccine that became known as “Coley’s toxin,” consisting of heat-killed streptococcal organisms combined with heat-killed Serratia marcescens (formerly known as Bacillus prodigiosus). Coley treated over 1000 cancer patients and achieved a high success rate in treatment of sarcomas, carcinomas (e.g. breast and renal cancer), lymphomas and melanomas. Coley’s toxin became the foundation for early cancer immunotherapy, only to be overshadowed by the emergence of radiation and chemotherapies.

Now cancer immunotherapy has come back to the fore, both due to the success of new immunotherapies and recognition of the limits of radiation and chemotherapies, with or without genomics. Science magazine in 2013 cited the first fruits of modern cancer immunotherapy with promising T-cell Receptor therapies, as mentioned. Fast forward two years, and cancer immunotherapy has become perhaps the most important area for experimental cancer therapies and cures.

The current impact and importance of immunotherapy for cancer R&D is perhaps best symbolized by the today’s launch of the Loncar Investments Cancer Immunotherapy Index. The Loncar Immunotherapy fund includes a companies ranging from diversified Fortune-100s to smaller companies focused exclusively on immunotherapy.

At least for now it does not include Amrita Therapeutics Ltd. – an Indian biotech-startup that I co-founded with Ananda Chakrabarty that builds on our increased understanding of the important therapeutic role of bacteria and related peptides in cancer therapy. Ananda has been saying for some time to anyone who will listen that the evolutionary wisdom of bacteria may lead to a new golden age for cancer therapies and broader drug development. For my part, I have learned that the future is a mystery.

Only hindsight is 20/20.

About the author:
President of Finston Consulting LLC since 2005, Susan works with innovative biotechnology and other clients ranging from start-up to Fortune-100, providing support for legal, transactional, policy and “doing business” issues. Susan has extensive background and special expertise relating to intellectual property and knowledge-economy issues in advanced developing countries including India and South Asia, Latin America and the Middle East North Africa (MENA) region. She also works with governments, and NGOs on capacity building and related educational programs through BayhDole25. Together with biotechnology pioneer Ananda Chakrabarty, she also is co-founder of Amrita Therapeutics Ltd., an emerging biopharmaceutical company based in India with cancer peptide drugs entering in vivo research. Previous experience includes 11 years in the U.S Foreign Service with overseas tours in London, Tel Aviv, and Manila and at the Department of State in Washington DC. For more information on latest presentations and publications please visit finstonconsulting.com.

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them

Click the patents below for more details, or visit DrugPatentWatch.com for more options.

NUVIGIL (armodafinil)
Cephalon
Patent number: RE 37,516
Expiration Date: Apr 6, 2015


PROVIGIL (modafinil)
Cephalon
Patent number: RE 37,516
Expiration Date: Apr 6, 2015


FLOVENT HFA (fluticasone propionate)
Glaxo Grp Ltd
Patent number: 5,674,472
Expiration Date: Apr 7, 2015


ADVAIR HFA (fluticasone propionate; salmeterol xinafoate)
Glaxo Grp Ltd
Patent number: 5,674,472
Expiration Date: Apr 7, 2015


HYCAMTIN (topotecan hydrochloride)
Glaxosmithkline
Patent number: 5,674,872
Expiration Date: Apr 7, 2015


For more information try a free trial

TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government.

Click the patents below for more details, or visit TechTransferWatch.com for more options.

ETP1 and ETP2 regulate plant ethylene response
Hong Qiao, Joseph R. Ecker
Salk Institute for Biological Studies
Patent number: 9,000,260
Issue Date: April 07, 2015


Fumarylacetoacetate hydrolase (fah)-deficient pigs and uses thereof
Markus Grompe, Scott Nyberg, Joseph Lillegard, Raymond Hickey, Markus Grompe, Scott Nyberg, Joseph Lillegard, Raymond Hickey
Oregon Health & Science University
Patent number: 9,000,257
Issue Date: April 07, 2015


Mangromicin compound and production method therefor
Satoshi Omura, Yoko Takahashi, Takuji Nakashima, Kazuhiko Otoguro, Kazuro Shiomi, Masato Iwatsuki, Atsuko Matsumoto
Kitasato Institute
Patent number: 9,000,194
Issue Date: April 07, 2015


Induced activation in dendritic cells
Baylor College of Medicine
Patent number: 8,999,949
Issue Date: April 07, 2015


Nucleic acid functionalized nanoparticles for therapeutic applications
Chad A. Mirkin, Nathaniel L. Rosi, C. Shad Thaxton, David A. Giljohann
Northwestern University
Patent number: 8,999,947
Issue Date: April 07, 2015


Antigene oligomers inhibit transcription
David Reid Corey, Bethany Ann Janowski
University of Texas System
Patent number: 8,999,943
Issue Date: April 07, 2015


Glial cell line-derived neurotrophic factor (GDNF) compositions and use thereof
Department of Health and Human Services
Patent number: 8,999,927
Issue Date: April 07, 2015


Compositions and methods for inhibiting the interaction between CFTR and CAL
Dean R. Madden, Patrick R. Cushing, Prisca Boisguearin, Rudolph Volkmer, Lars Vouilleme
Dartmouth
Patent number: 8,999,919
Issue Date: April 07, 2015


Discovery and applications of the proteolytic function of N-terminal acetylation of cellular proteins
Cheol-Sang Hwang, Anna Shemorry, Alexander Varshavsky
California Institute of Technology
Patent number: 8,999,896
Issue Date: April 07, 2015


Method of making hybrid cells that express useful antibodies
Scott K. Dessain, Sharad P. Adekar
Thomas Jefferson University
Patent number: 8,999,707
Issue Date: April 07, 2015


Methods for preparation of human hair-follicle derived multipotent adult stem cells
Xiaowei Xu, Hong Yu, Douglas Dong Fang, Meenhard Herlyn, Xiaowei Xu, Hong Yu, Douglas Dong Fang, Meenhard Herlyn
Wistar Institute
Patent number: 8,999,706
Issue Date: April 07, 2015


Bifidobacterial gene sequences and their use
University of California
Patent number: 8,999,705
Issue Date: April 07, 2015


Inhibitor tolerant
Zonglin L. Liu
Department of Agriculture
Patent number: 8,999,701
Issue Date: April 07, 2015


Polysaccharide-protein binding model and nano-fibril formation of a starch binding domain
Margaret Dah-Tsyr Chang, Yuh-Ju Sun, Ping-Chiang Lyu, Shu-Chuan Lin, Wei-I Chou
National Tsing Hua University
Patent number: 8,999,688
Issue Date: April 07, 2015


Method for specifically producing a joined DNA fragment comprising a sequence derived from a target gene
Nobuyuki Kurosawa, Masaharu Isobe
University of Toyama
Patent number: 8,999,673
Issue Date: April 07, 2015


Glycosylated protein expression in prokaryotes
Matthew DeLisa, Cassandra Guarino, Thomas Mansell, Adam Fisher
Cornell University
Patent number: 8,999,668
Issue Date: April 07, 2015


Compositions for detecting cell death and methods of use thereof
Andrew Kung, Pallab Banerjee
Dana-Farber Cancer Institute
Patent number: 8,999,661
Issue Date: April 07, 2015


Increase of myeloid microvesicles in the cerebrospinal fluid as biomarker of microglia/macrophage activation in neurological disorders
Claudia Verderio, Michela Matteoli, Roberto Furlan, Claudia Verderio, Michela Matteoli, Roberto Furlan
University of Milan
Patent number: 8,999,655
Issue Date: April 07, 2015


Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
, , , , ,
Harvard
Patent number: 8,999,641
Issue Date: April 07, 2015


Compositions, kits, and methods for identification, assessment, prevention and treatment of pancreatic adenocarcinoma in humans
Lynda Chin, Cameron W. Brennan, Ronald A. DePinho, Andrew J. Aguirre
Dana-Farber Cancer Institute
Patent number: 8,999,633
Issue Date: April 07, 2015


Polyclonal bispecific antibody compositions and method of use
Lawrence Lum, Manley Huang
Wayne State University
Patent number: 8,999,398
Issue Date: April 07, 2015


Immunogenic control of tumours and tumour cells
Jean-Marie Saint-Remy
University of Leuven
Patent number: 8,999,346
Issue Date: April 07, 2015


Methods and compositions related to the structure and function of APOBEC3G
Harold C. Smith, Joseph E. Wedekind, Ryan Patrick Bennett
University of Rochester
Patent number: 8,999,317
Issue Date: April 07, 2015


MCPIP as wound therapy
Pappachan E. Kolattukudy, Jianli Niu
University of Central Florida
Patent number: 8,999,314
Issue Date: April 07, 2015


Compositions and methods for the removal of biofilms
Steven D. Goodman, Lauren O. Bakaletz
University of Southern California
Patent number: 8,999,291
Issue Date: April 07, 2015


Feeder-free method for culture of bovine and porcine spermatogonial stem cells
Washington State University
Patent number: 8,998,793
Issue Date: April 07, 2015